According to the latest research definition, AD can be diagnosed in vivo, independently of cognitive manifestations, by the means of biomarkers reflecting β-amyloid deposition, tau pathology, and neurodegeneration [3]. This evidence concerns the gene MAPT and Alzheimer disease.